Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 14, Suppl. 1, 2005
Issue release date: July 2005
Section title: Review
Open Access Gateway
Med Princ Pract 2005;14:35–48

Mechanisms of Drug Resistance in Cancer Chemotherapy

Luqmani Y.A.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait
email Corresponding Author

Prof. Y.A. Luqmani

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University

PO Box 24923

13110 Safat (Kuwait)

Tel. +965 533 7135, Fax +965 5342807, E-Mail yunus@hsc.edu.kw


  1. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1–11.
  2. Gross ME, Shazer RL, Agus DB: Targeting the HER-kinase axis in cancer. Semin Oncol 2004;31:9–20.
  3. Finn RS, Slamon DJ: Monoclonal antibody therapy for breast cancer: Herceptin. Cancer Chemother Biol Response Modif 2003;21:223–233.
    External Resources
  4. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21–26.
  5. Gruner BA, Weitman SD: The folate receptor as a potential therapeutic anticancer target. Invest New Drugs 1999;16:205–219.
  6. Reddy JA, Low PS: Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998;15:587–627.
  7. Zamble DB, Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20:435–439.
  8. Hurley LH: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002;2:188–200.
  9. Kast C, Gros P: Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence. J Biol Chem 1997;272:26479–26487.
  10. Kast C, Gros P: Epitope insertion favors a six transmembrane domain model for the carboxy-terminal portion of the multidrug resistance-associated protein. Biochemistry 1998;37:2305–2313.
  11. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156–1166.
  12. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152–162.
  13. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381–389.
  14. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human ‘MDR1’ gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004–3008.
  15. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I: Genetic analysis of the multidrug transporter. Annu Rev Genet 1995;29:607–643.
  16. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989;58:137–171.
  17. Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol 1992;8:67–113.
  18. Gottesman MM, Pastan I, Ambudkar SV: P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996;6:610–617.
  19. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
  20. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650–1654.
  21. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295–1302.
  22. Cole SP, Deeley RG: Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998;20:931–940.
  23. Litman T, Druley TE, Stein WD, Bates SE: From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931–959.
  24. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 2000:57:24–35.
  25. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000;275:23530–23539.
  26. Kool M, van der Inden M, de Haas M, Baas F, Borst P: Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 1997;57:3537–3547.
  27. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995;111:1301–1310.
    External Resources
  28. Homolya L, Varadi A, Sarkadi B: Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucoronate or sulfate. Biofactors 2003;17:103–114.
  29. Haimeur A, Conseil G, Deeley RG, Cole SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21–53.
  30. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995;92:7690–7694.
  31. Schinkel, AH: The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8:161–170.
  32. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–7738.
  33. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451–2458.
  34. Gottesman MM, Pastan I, Ambudkar SV: P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996;6:610–617.
  35. Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1–6.
  36. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ: A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000;38:1–11.
  37. Shapiro AB, Fox K, Lam P, Ling V: Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999;259:841–850.
  38. Sikic BI, Fisher GA, Lum BA, Halsey J, Beketic-Oreskovic L, Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40(suppl):S13–S19.
    External Resources
  39. Lin JH, Yamazaki M: Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003;35:417–454.
  40. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV: Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol Oncol 2004;93:98–106.
  41. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R: The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 2000;38:94–110.
  42. Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dorken B, Ludwig WD: Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85:711–721.
  43. Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, Giustolisi GM, Pavone B, Palumbo GA, Di Raimondo F, Milone G, Guglielmo P, Giustolisi R: Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002;116:774–780.
  44. Kumta SM, Zhu QS, Lee KM, Griffith J, Chow LT, Leung PC: Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma. Int Orthop 2001;25:279–282.
  45. Leonessa F, Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10:43–73.
  46. Roepe PD: What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance? Curr Pharm Des 2000;6:241–60.
  47. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998;12:7024–7029.
  48. Henkart PA: ICE family proteases: Mediators of all apoptotic cell death? Immunity 1996;4:195–201.
  49. Johnstone RW, Cretney E, Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075–1085.
  50. Ruefli AA, Smyth MJ, Johnstone RW: HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000;95:2378–2385.
  51. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW: P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 2002;9:1266–1272.
  52. Cullen KV, Davey RA, Davey MW: Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leuk Res 2001;25:69–75.
  53. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000;157:1575–1580.
  54. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147–153.
  55. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T: Gene rearrangement: A novel mechanism for MDR-1 gene activation. J Clin Invest 1997;99:1947–1957.
  56. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473–3478.
  57. Dive C, Hickman JA: Drug-target interactions: Only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192–196.
  58. Petty R, Evans A, Duncan I, Kurbacher C and Cree I: Drug resistance in ovarian cancer – The role of p53. Pathol Oncol Res 1998;4:97–102.
  59. Grunicke H: Oncogenes and drug resistance. Deutsche Krebsgesellschaft e.V. Materials, 23rd Congr, Berlin, June 8–12, 1998.
  60. Johnson KR, Fan W: Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002;22:3197–3204.
  61. Selivanova G: Mutant p53: The loaded gun. Curr Opin Investig Drugs 2001;2:1136–1141.
  62. Burger, H, Nooter K, Boersma AWM, Van Wingerden KE, Looijenga LHJ, Jochemsen AG, Stoter G: Distinct p53-independent apoptotic cell death signaling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999;81:629–628.
  63. Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, Margel M, Felip E, Mendez P, Garcia-Campelo R: Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004;31:20–27.
  64. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787–790.
  65. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity indrug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855–1865.
  66. Dunn TA, Schmoll HJ, Grunwald V, Bokemeyer C, Casper J: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997;15:109–114.
  67. Miller WR: Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18:1–32.
  68. Campos SM: Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126–136.
  69. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
  70. Duesberg P, Stindl R, Hehlmann R: Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome re-assortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 2000;97:14295–14300.
  71. Duesberg P, Stindl R, Hehlmann R: Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome re-assortments catalyzed by aneuploidy. Proc Natl Acad Sci USA 2001;98:11283–11288.
  72. Ramakrishnan P: The role of P-glycoprotein in the blood-brain barrier. Einstein Q J Biol Med 2003;19:160–165.
  73. Tatsuta T, Naito M, Oh-Hara T, Sugawara I, Tsuruo T: Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992;267:20383–20391.
  74. Hughes CS, Vaden SL, Manaugh CA, Price GS, Hudson LC: Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J Neurooncol 1998;37:45–54.
  75. Begley DJ: ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10:1295–1312.
  76. Cytochrome CYP450 standardised nomenclature committee website: http://drnelson.utmem.edu/CytochromeP450.html.
  77. Waxman DJ: P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11–23.
  78. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271–1294.
  79. Gamcsik MP, Dubay GR, Cox BR: Increased rate of glutathione synthesis from cystine in drug-resistant MCF-7 cells. Biochem Pharmacol 2002;63:843–851.
  80. Deng HB, Parekh HK, Chow KC, Simpkins H: Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 2002;277:15035–15043.
  81. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, MacKey J: Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106:78–85.
  82. Hofmann J: Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 2004;4:125–146.
  83. Aoudjit F, Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001;20:4995–5004.
  84. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M: Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001;61:8851–8858.
  85. Song S, Wientjes MG, Gan Y, Au JL: Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658–8663.
  86. Kern DH, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;82:582–588.
  87. McGuire WL, Kern DH, Von Hoff DD, Weisenthal LM: In vitro assays to predict drug sensitivity and drug resistance. A panel discussion. Breast Cancer Res Treat 1988;12:7–21.
  88. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68:231–237.
  89. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995;31A:1295–1298.
  90. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T, et al: Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991;83:1386–1391.
  91. Mechetner EB, Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89:5824–5828.
  92. Pawlak W, Zolnierek J, Sarosiek T, Szczylik C: Antisense therapy in cancer. Cancer Treat Rev 2000;26:333–350.
  93. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
  94. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2000;411:494–498.
  95. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31–36.
  96. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045–1047.
  97. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15–R24.
  98. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
  99. Messa C, Russo F, Caruso MG, Di Leo A: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998;37:285–289.
  100. Porebska I, Harlozinska A, Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105–115.
  101. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
  102. Saltz L, Rubin MS, Hochster HS: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor (abstract). Prog Proc Am Soc Clin Oncol 2001;20:3a.
  103. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201–1208.
  104. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.
  105. Chen ZS, Furukawa T, Sumizawa T: ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999;55:921–928.
  106. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y: Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 1999;288:735–741.
  107. Meyers MB, Merluzzi VJ, Spengler BA, Biedler JL: Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc Natl Acad Sci USA 1986;83:5521–5525.
  108. Meyers MB, Yu P, Mendelsohn J: Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. Biochem Pharmacol 1993;46:1841–1848.
  109. Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002;98:310–315.
  110. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ: Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 2003;7:37–43.
  111. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R: Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998;273:1568–1573.
  112. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166–2174.
  113. Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003;39:1348–1354.
  114. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
  115. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987–989.
  116. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145–147.
  117. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361–398.
  118. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I, Gottesman MM: Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 1993;268:27127–27132.
  119. Sorrentino BP: Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2002;2:431–441.
  120. Schoenfield A, Luqmani YA, Sinnett HD, Shousha S, Coombes RC: Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Br J Cancer 1996;74:1639–1642.
  121. Pantel K, von Knebel Doeberitz M: Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol 2000;12:95–101.
  122. Zehentner BK: Detection of disseminated tumor cells: Strategies and diagnostic implications. Expert Rev Mol Diagn 2002;2:41–48.